MedTrace Logo

Experimental Autologous Mesenchymal Stem Cell Therapy in Treatment of Chronic Autoimmune Urticaria

NCT02824393 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2018-07-18

No results posted yet for this study

Summary

The aim of this study is to determine whether autologous adipose tissue derived Mesenchymal Stem Cells of treatment for chronic autoimmune urticaria is safe and effective.

Conditions

Interventions

BIOLOGICAL

Autologous mesenchymal stem cell

Intravenous infusion of ex vivo cultured adipose tissue derived autologous mesenchymal stem cells, twice at two week intervals in total 1x10/6 cells/kg.

Sponsors & Collaborators

  • The Scientific and Technological Research Council of Turkey

    collaborator OTHER

  • Acıbadem Labcell

    collaborator OTHER

  • Celal Bayar University

    lead OTHER

Principal Investigators

  • Alper Tunga Özdemir, PhD · Ege University, Institute of Health Sciences, Department of Stem Cell, Izmir/TURKEY

  • Ercüment Ovalı, Prof. Dr. · Acıbadem Labcell, Istanbul/TURKEY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-03
Primary Completion
2018-05-15
Completion
2018-07-15

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02824393 on ClinicalTrials.gov